Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($0.05), $0.95 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $145 million versus the consensus estimate of $30.88 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.